Background-The sulfonylurea glibenclamide (Glib) abolishes the cardioprotective effect of ischemic preconditioning (IP), presumably by inhibiting mitochondrial K ATP channel opening in myocytes. Glimepiride (Glim) is a new sulfonylurea reported to affect nonpancreatic K ATP channels less than does Glib. We examined the effects of Glim on IP and on the protection afforded by diazoxide (Diaz), an opener of mitochondrial K ATP channels. Methods and Results-Rat hearts were Langendorff-perfused, subjected to 35 minutes of regional ischemia and 120 minutes of reperfusion, and assigned to 1 of the following treatment groups: (1) control;
S ulfonylureas are drugs used in the treatment of type 2 diabetes. They inhibit ATP-sensitive potassium (K ATP ) channels, which induce membrane depolarization and an influx of calcium in pancreatic ␤-cells. Calcium acts as a second messenger, accounting for insulin release into the bloodstream. 1 However, it has been suggested that classic sulfonylureas such as tolbutamide and glibenclamide (also known as glyburide) may have adverse effects on the cardiovascular system, mainly because they also close mitochondrial K ATP channels, thought to play a central role in ischemic preconditioning (IP) protection. [1] [2] [3] Glimepiride is a newer sulfonylurea derivative demonstrated to have fewer cardiac actions than other sulfonylureas in both animal 4 and human 5 studies. For example, Geisen et al 4 showed that glimepiride blocked K ATP currents in isolated rat cardiomyocytes at a concentration 5-fold higher than glibenclamide. There are also data providing indirect evidence that glibenclamide, but not glimepiride, prevents pre-conditioning in humans subjected to balloon angioplasty. 6 If glimepiride has fewer cardiac actions than other sulfonylureas, then this would have important implications for its preferred use in the treatment of patients with type 2 diabetes with concurrent coronary artery disease.
The aim of this study was to compare the effect of glimepiride and the more conventionally used sulfonylurea glibenclamide on IP protection and on the protection afforded by one of the preconditioning mimetic agents, diazoxide. Diazoxide is a K ATP channel opener exhibiting selectivity for mitochondrial K ATP channels at concentrations up to 30 mol/L. 7 In this study, we used infarct size as the end point of injury, because this measure is a robust indicator of preconditioning-induced protection. We also assessed the effect of glimepiride and glibenclamide directly on sarcolemmal K ATP channel currents in isolated ventricular myocytes in addition to their effect on membrane potential in isolated cardiac mitochondria.
Methods

Animals
Male Sprague-Dawley rats (350Ϯ30 g body weight) were used. All animals were obtained from the same source (Charles River UK Limited, Margate, UK), fed a standard diet, housed under the same conditions, and received humane care in accordance with The Guidance on the Operation of the Animals (Scientific Procedures) Act 1986.
Isolated Heart Perfusion
Rats were anesthetized with sodium pentobarbital (55 mg/kg intraperitonally) and given heparin sodium (300 IU). Hearts were excised, arrested in ice-cold buffer, and mounted on a constant-pressure (80 mm Hg) Langendorff perfusion system. They were perfused retrogradely with a modified Krebs-Henseleit bicarbonate buffer containing the following chemicals (in mmol/L): NaCl 118.5, NaHCO 3 25.0, KCl 4.8, MgSO 4 1.2, KH 2 PO 4 1.2, CaCl 2 1.7, and glucose 12.0. All solutions were filtered through a Whatman 2.0-m microfilter and gassed with 95%O 2 /5% CO 2 (pH 7.35 to 7.50 at 37°C). Temperature was continuously monitored by a thermoprobe inserted into the right ventricle. A latex, fluid-filled, isovolumic balloon was introduced into the left ventricle through the left atrial appendage and inflated to give a preload of 8 to 10 mm Hg. Left ventricular developed pressure, heart rate, and coronary flow were registered at regular intervals. A surgical needle was passed under the left main coronary artery, and the ends of the thread were passed through a small plastic tube to form a snare. Regional ischemia was induced by tightening the snare, and reperfusion was started by releasing the ends of the thread.
Treatment Protocols
The experimental protocols are presented in Figure 1 . Glibenclamide, glimepiride, and diazoxide were dissolved in dimethyl sulfoxide and added to the Krebs-Henseleit buffer such that the final dimethyl sulfoxide concentration did not exceed 0.02%. The hearts were randomly assigned to 1 of 9 treatment groups: (1) Control hearts (nϭ9) were perfused with 0.02% dimethyl sulfoxide for 20 minutes during stabilization before 35 minutes of regional ischemia and 120 minutes of reperfusion. (2) IP hearts (nϭ7) were treated with 2 periods of 5 minutes each of global ischemia with a 10-minute intervening reperfusion before 35 minutes of regional ischemia and 120 of minutes reperfusion. (3) Hearts (nϭ9) were perfused with 30 mol/L diazoxide for 20 minutes immediately before regional ischemia. (4) Hearts (nϭ6) were perfused with 10 mol/L glimepiride for 20 minutes immediately before regional ischemia. (5) Hearts (nϭ6) were perfused with 10 mol/L glibenclamide for 20 minutes immediately before regional ischemia. (6) Hearts (nϭ8) underwent the IP protocol in the presence of 10 mol/L glimepiride. The drug was added to the perfusate 20 minutes before starting the preconditioning protocol and was present throughout this protocol. The buffer was switched to normal Krebs-Henseleit buffer after the onset of regional ischemia. (7) Hearts (nϭ7) underwent the IP protocol in the presence of 10 mol/L glibenclamide as in group 6. (8) Hearts (nϭ9) were coperfused with 30 mol/L diazoxide and 10 mol/L glimepiride for 20 minutes immediately before regional ischemia. (9) Hearts (nϭ8) were coperfused with 30 mol/L diazoxide and 10 mol/L glibenclamide for 20 minutes immediately before regional ischemia.
Infarct Size Measurement
At the end of the reperfusion period the snare was tightened to reocclude the coronary artery, and a saline solution of 0.12% Evans blue was infused slowly by way of the aorta. This procedure delineated the nonischemic zone of the myocardium as a dark blue area. After 1 to 4 hours at Ϫ20°C, hearts were sliced into 1-mm-thick transverse sections and incubated in triphenyltetrazolium chloride solution (1% in phosphate buffer, pH 7.4) at 37°C for 10 to 15 minutes. The tissue slices were then fixed in 10% formalin. At the end of this procedure, in the risk zone the viable tissue was stained red and the infarcted tissue appeared pale. The slices were drawn onto acetate sheets. With the use of a computerized planimetry package (Summa Sketch II, Summagraphics), the percentage of infarcted tissue within the volume of myocardium at risk was calculated.
Patch-Clamp Studies
Ventricular myocytes were isolated from adult rat hearts by enzymatic dissociation as previously described. 8 Cells were stored at 10°C to 12°C and bathed in a solution containing the following constituents (in mmol/L): NaCl 135.0, KCl 6.0, CaCl 2 2.0, MgCl 2 1.0, NaH 2 PO 4 0.33, sodium pyruvate 5, and HEPES 10.0, pH 7.4. The intracellular (pipette) solution contained the following constituents (in mmol/L): KCl 140.0, MgCl 2 1.0, EGTA 5.0, ATP 2.0, ADP 0.1, GTP 0.1, and HEPES 10.0, pH 7.2. Currents were recorded by using conventional patch-clamp techniques with an Axopatch 200B amplifier, analyzed with pCLAMP 8 software, and expressed relative to cell size as picoamps per picofarad. Experiments were performed at 30°C.
Studies in Isolated Cardiac Mitochondria
Mitochondria were isolated from rat hearts by using a previously described technique. 9 After extraction the mitochondria were kept on ice, and an aliquot was suspended in KCl buffer containing (in mmol/L) KCl 45.0, potassium acetate 25.4, TES 5.0, EGTA 0.1 (pH 7.4), MgCl 2 1.0, and 10 mol/L cytochrome c. Substrates for respiration were 2.5 mmol/L ascorbate and 0.25 mmol/L NЈ,NЈ,NЈ,NЈ-tetramethyl-P-phenylene diamine. Aliquots of mitochondria were incubated with the mitochondrial membrane potential-sensitive dye tetramethylrhodamine methyl ester (TMRM, 200 nmol/L) 10 at room temperature for 5 minutes before drug intervention. Where indicated, the physiological K ATP channel opener GTP (50 mol/L) was added to the TMRM-stained mitochondria 2 minutes before measurements of fluorescence in the absence or presence of 5-hydroxydecanoate (a mitochondrial K ATP channel inhibitor, 100 mol/L), glibencamide (10 mol/L), and glimepiride (10 mol/L). The mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (1 mol/L) was used as a positive control. Cytofluorometric analysis was done on a Coulter Epics flow cytometer equipped with a 488-nm argon laser. The TMRM signal was analyzed in the FL2 channel equipped with a band-pass filter at 580Ϯ30 nm; the photomultiplier value of the detector was 631 V. Data were acquired on a logarithmic scale. Arithmetic mean values of the median fluorescence intensities were determined for each sample for graphic representation. Experiments were performed on mitochondria isolated from 6 individual rats, each experiment representing 15 000 mitochondria.
Statistical Analysis
All values are expressed as meanϮSEM. Data were analyzed by 1-way ANOVA and Fisher's protected least significant difference test for multiple comparisons. Differences were considered significant for PϽ0.05.
Results
Exclusions
We used a total of 76 rat hearts for the Langendorff perfusion study. Of these, 6 were excluded owing to poor function during stabilization.
Hemodynamic Data
Baseline data relating to cardiac function and coronary flow rates before regional ischemia where similar in all experimental groups. During regional ischemia, coronary flow and left ventricular developed pressure decreased to a similar extent in all groups. An increase in coronary flow during the first minutes of reperfusion was indicative of successful reflow, but coronary flow subsequently declined in all groups during the following 120-minute reperfusion period. During reperfusion, left ventricular developed pressure recovered gradually, though never reaching stabilization values.
Infarct Size Data
The risk zone volume was similar in all experimental groups, at Ϸ0.5 cm 3 . Infarct size is represented as the percentage of tetrazolium-negative tissue in the ischemic risk zone. As expected, IP significantly reduced the amount of infarcted tissue in the risk zone compared with control hearts (18.6Ϯ1.5% vs 43.7Ϯ3.0%, PϽ0.01; Figures 2 and 3) . Glimepiride or glibenclamide alone did not influence infarct size (glibenclamide 44.7Ϯ5%, glimepiride 41.4Ϯ4.7%). However, when administered before and during the IP protocol, glibenclamide abolished the protective effect of preconditioning (36.3Ϯ4% in glibenclamideϩIP vs 18.6Ϯ1.5% in IP, PϽ0.05), whereas glimepiride did not (18.5Ϯ2.7% in glimepirideϩIP vs 18.6Ϯ1.5% in IP; Figure 2 ).
With regard to potential effects on the mitochondria, we used the K ATP channel opener diazoxide to investigate the differences between glibenclamide and glimepiride. Diazoxide alone given before ischemia also conferred protection against ischemia/reperfusion injury (infarct/risk zone, 22.2Ϯ4.7%; PϽ0.05 vs control). This beneficial effect was lost in the presence of glibenclamide (22.2Ϯ4.7% in diazoxide vs 38.8Ϯ5% in diazoxideϩglibenclamide; PϽ0.05) but not in the presence of glimepiride (22.4Ϯ2.9% in diazoxideϩglimepiride vs 22.2Ϯ4.7% in diazoxide; PϾ0.05; Figure 3 ).
Patch-Clamp Studies
To test whether glimepiride and diazoxide affect currents through sarcolemmal K ATP channels of rat ventricular myocytes, we used patch-clamp techniques to record whole-cell membrane currents at a holding potential of 0 mV in 6 mmol/L K ϩ solution. Under these conditions, the K ATP channel opener pinacidil activated a substantial outward K ATP current, which was blocked by both 1 mol/L glimepiride ( Figure 4A ) and 1 mol/L glibenclamide ( Figure 4B ). The effectiveness of glimepiride in blocking sarcolemmal K ATP channels was confirmed in 16 additional cells. In experiments in which we tested different concentrations, half blockage occurred with Ϸ10 nmol/L glimepiride. In similar experiments, we looked for current activation by diazoxide (at 30 and 300 mol/L). Figure 4B shows that no activation of current was detectable in response to diazoxide at 300 mol/L, but the subsequent application of pinacidil (200 mol/L) to the same cell activated substantial K ATP current. The results from several cells ( Figure 4C) show that diazoxide caused no activation of sarcolemmal K ATP current at either 30 or 300 mol/L. These results suggest that glibenclamide and glimepiride are potent blockers of sarcolemmal K ATP channels in rat ventricular myocytes and that diazoxide does not activate these channels under our experimental conditions.
Mitochondrial Membrane Potential
Ascorbate was used in all experiments as a mitochondrial respiratory substrate. Application of ascorbate to the mitochondria caused an instantaneous increase in intensity of TMRM fluorescence, concomitant with mitochondrial membrane polarization. The mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (1 mol/L), used as a positive control to collapse membrane potential in the mitochondria, resulted in a large reduction in intensity of TMRM fluorescence ( Figure  5A ). Treatment of mitochondria with the physiological mitochondrial K ATP channel opener GTP (50 mol/L) significantly (PϽ0.0001) decreased the TMRM fluorescence from 153Ϯ3.9 arbitrary fluorescence units in untreated mitochondria to 135Ϯ2.9 ( Figure 5A ). GTP significantly decreased the mitochondrial membrane potential by 14Ϯ0.9% of the control value ( Figure 5B ). 5-Hydroxydecanoate, glimepiride, or glibenclamide alone had no effect on membrane potential ( Figure 5B ). Both glibencamide and 5-hydroxydecanoate prevented the changes in membrane potential induced by GTP (150Ϯ4.7 and 150Ϯ3.8 arbitrary units, respectively, compared with control 153Ϯ3.9), whereas glimepiride did not block these changes (132Ϯ2.9 arbitrary units; Figures 5A and 5B ).
Discussion
Diabetes is a common and widespread disease. In the diabetic population, 90% of patients have type 2 diabetes. 11 In these patients there is an increased risk of cardiovascular complications followed by higher morbidity and mortality than in a nondiabetic population with coronary artery disease. 12 The most common treatment approach in type 2 diabetes is administration of oral sulfonylureas, such as glibenclamide, which block K ATP channels, thereby stimulating insulin re-lease by pancreatic ␤-cells. Unfortunately, K ATP channel blockade is not specific to the pancreas and can affect other tissues as well. It is well established that glibenclamide can also block sarcolemmal K ATP channels in a number of other cell types, including vascular smooth muscle cells, cardiac myocytes, and vascular endothelium, as well as the K ATP channels situated on the inner membrane of mitochondria. 13 Figure 4 . Effects of sulfonylureas and diazoxide on sarcolemmal K ATP current. A, Membrane current recorded from isolated rat ventricular myocyte by using whole-cell patch-clamp technique. Cell was held at 0 mV throughout, and extracellular solution contained 6 mmol/L K ϩ . Application of K ATP channel opener pinacidil activated outward K ATP current, which was completely blocked by 1 mol/L glimepiride. B, Recording from different cell under same conditions as in A. Diazoxide (300 mol/L) did not activate K ATP current, but subsequent application of pinacidil (200 mol/L) activated substantial current that was inhibited by 1 mol/L glibenclamide. C, MeanϮSEM sarcolemmal K ATP (glibenclamide-sensitive) current at 0 mV in absence of K ATP channel openers (6K), in presence of diazoxide (30 and 300 mol/L) or pinacidil (200 mol/L). nϭ5 cells in each case. *PϽ0.0001 vs 6K, t test. There is also substantial evidence to suggest that in diabetic patients with acute myocardial infarction, these oral agents should be avoided. 14 Initial concern for issue this was raised in the early 1970s when the University Group Diabetes Program assessed the efficacy of oral hypoglycemic treatment compared with insulin and diet alone in the prevention of cardiovascular complications. 15 They demonstrated a significantly higher cardiovascular mortality in patients on sulfonylureas compared with diet alone. Nonetheless, these agents have continued to be extensively used because, one suspects, of the lack of a plausible mechanism for the University Group Diabetes Program study results. The United Kingdom Prospective Diabetes Study, a large-scale clinical study of Ͼ5000 patients, 16 attempted to answer the question of whether improved glycemic control reduced the risk of cardiovascular death in patients who were taking insulin and sulfonylureas. In that study no detrimental effect of sulfonylureas was noted, and the United Kingdom Prospective Diabetes Study is often cited as proof that sulfonylureas such as glibenclamide do not pose a risk to patients with type 2 diabetes. Unfortunately, what the study failed to ascertain was the effect that these agents had on these type 2 diabetic patients in the setting of acute coronary syndromes, ie, in patients directly at risk of myocardial infarction (presenting with chest pain or unstable angina).
In this context, one of the most potent mechanisms of protection against myocardial ischemia/reperfusion injury is ischemic preconditioning. 17 This endogenous protective response has been demonstrated in all species, including humans, 18 and has been described as the beneficial adaptive response of the myocardium to repeated episodes of sublethal ischemia. A substantial body of evidence implicates mitochondrial K ATP channel opening as playing a central role in the acquisition of this protection. 3, 19 Although it is not clearly established whether mitochondrial K ATP channel opening plays a trigger role (proximal event) or acts as a distal effector of protection, glibenclamide has been shown to attenuate this preconditioning response in animal studies (for a review, see Yellon et al 18 ). There are also data from human studies in which preconditioning has been examined with surrogate end points such as ST-segment deviation during repeated intracoronary balloon inflations that support the notion that glibenclamide blunts the preconditioning response. 20 Such observations have generated concern about the safety of sulfonylurea agents in diabetic patients with concurrent ischemic heart disease, because inhibition of the endogenous preconditioning mechanism by sulfonylureas might predispose to cell death. 1 Glimepiride, a second-generation sulfonylurea, has been shown to be more specific to the pancreas than to other tissues, especially the myocardium. 4 Furthermore, glimeperide was shown to have a more rapid as well as longer duration of action, and despite stimulating less insulin secretion in comparison with glibenclamide, it has been shown to have higher glucose-decreasing activity. 13, 21 This characteristic may be as a consequence of its having a direct effect on the expression of glucose transporters, such as Glut-1 and Glut-4. 22 Our aim was to study the direct effect of these sulfonylurea drugs on the protection conferred by ischemic precondition-ing by using infarct size, which has been shown to be a valid end point in relation to experimental preconditioning studies. 23 The results show that infarct size reduction due to ischemic preconditioning was not significantly changed when the preconditioning protocol took place in the presence of glimepiride. On the contrary, glibenclamide completely abolished this protection. A possible explanation would be that unlike glibenclamide, glimepiride does not block the mitochondrial K ATP channels, known to play a crucial role in preconditioning protection. To examine this hypothesis, the second aim of our study was to ascertain whether glimepiride abolished the protective role of diazoxide, a known opener of mitochondrial K ATP channels at specific doses. 7 It has been shown that diazoxide, when administered before ischemia, protects the infarcting myocardium; 19 this beneficial effect being lost in the presence of glibenclamide. 7 Our results confirm these studies with respect to glibenclamide but also demonstrate that glimepiride does not appear to abolish this protective effect; ie, the protection conferred by diazoxide is not lost even when the mitochondrial K ATP opener is given in the presence of this sulfonylurea. The most plausible explanation would be that glimepiride does not affect mitochondrial K ATP opening, whereas glibenclamide blocks this channel. We do note, however, that 10 mol/L glibenclamide may not be specific, and we cannot exclude the possibility that at this concentration, glibenclamide abolishes other mechanisms involved in preconditioning.
Diazoxide has been shown to cause a decrease in mitochondrial membrane potential, although the exact process by which it does so remains controversial. 3,24 -26 Although diazoxide has been proposed to directly open mitochondrial K ATP channels, it may in addition have a nonspecific effect on electron transport of the respiratory chain. 3, 25, 26 To concentrate on the mitochondrial K ATP channel specifically, the physiological mitochondrial K ATP channel opener GTP was therefore used to investigate the action of the two sulfonylureas. 27 GTP produced a decrease in mitochondrial membrane potential, which was blocked by glibenclamide, as well as by a suitable agent known to block mitochondrial K ATP channels, viz, 5-hydroxydecanoate. Under the same conditions, glimepiride failed to inhibit the effects of GTP on mitochondrial membrane potential. These data indicate that glimepiride has no effect on mitochondrial K ATP channel opening by GTP.
We believe that more studies, basic as well as clinical, are needed to fully elucidate and characterize the role of this sulfonylurea. At present, we believe that our study undertaken in the isolated rat heart demonstrates that glimepiride appears to be significantly less harmful to the ischemic heart than is the more conventionally used sulfonylurea glibenclamide. Further work in other species and in vivo are warranted. However, the present data may have important implications for the treatment of type 2 diabetes patients at risk of myocardial infarction, and appropriate clinical studies would need to be designed to ascertain the true nature of the role and place of such sulfonylureas in ischemic heart disease patients.
